ATE402922T1 - 3-aminopyrrolidonderivate - Google Patents
3-aminopyrrolidonderivateInfo
- Publication number
- ATE402922T1 ATE402922T1 AT04819593T AT04819593T ATE402922T1 AT E402922 T1 ATE402922 T1 AT E402922T1 AT 04819593 T AT04819593 T AT 04819593T AT 04819593 T AT04819593 T AT 04819593T AT E402922 T1 ATE402922 T1 AT E402922T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- trifluoromethyl
- hydroxy
- optionally substituted
- independently hydrogen
- Prior art date
Links
- YNDAMDVOGKACTP-UHFFFAOYSA-N 3-aminopyrrolidin-2-one Chemical class NC1CCNC1=O YNDAMDVOGKACTP-UHFFFAOYSA-N 0.000 title abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Chemical group 0.000 abstract 1
- 208000012931 Urologic disease Diseases 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 208000014001 urinary system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Materials For Medical Uses (AREA)
- Ropes Or Cables (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03026779A EP1533298A1 (de) | 2003-11-21 | 2003-11-21 | 3-aminopyrrolidonederivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402922T1 true ATE402922T1 (de) | 2008-08-15 |
Family
ID=34429414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04819593T ATE402922T1 (de) | 2003-11-21 | 2004-11-16 | 3-aminopyrrolidonderivate |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7968592B2 (de) |
| EP (2) | EP1533298A1 (de) |
| JP (1) | JP2007511564A (de) |
| KR (1) | KR101208390B1 (de) |
| CN (1) | CN1882536A (de) |
| AT (1) | ATE402922T1 (de) |
| AU (1) | AU2004295048B2 (de) |
| BR (1) | BRPI0416816B8 (de) |
| CA (1) | CA2546653C (de) |
| CY (1) | CY1108359T1 (de) |
| DE (1) | DE602004015497D1 (de) |
| DK (1) | DK1685103T3 (de) |
| ES (1) | ES2309600T3 (de) |
| IL (1) | IL175754A (de) |
| MX (1) | MXPA06005626A (de) |
| NO (1) | NO337679B1 (de) |
| NZ (1) | NZ547295A (de) |
| PL (1) | PL1685103T3 (de) |
| PT (1) | PT1685103E (de) |
| RU (1) | RU2395495C2 (de) |
| SI (1) | SI1685103T1 (de) |
| WO (1) | WO2005054190A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017017619A2 (pt) * | 2015-02-19 | 2018-05-08 | Purdue Pharma Lp | métodos e composições para diminuir esvaziamento gástrico |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4924916B1 (de) * | 1970-08-14 | 1974-06-26 | ||
| SU671273A1 (ru) * | 1977-07-20 | 1982-07-07 | Предприятие П/Я Р-6225 | Металлические соли N-(1-окси-2,2,2-трихлорэтил)-пирролидона или -тиопирролидона,обладающие угнетающим действием на центральную нервную систему |
| GB8823605D0 (en) | 1988-10-07 | 1988-11-16 | Merck Sharp & Dohme | Therapeutic agents |
| CA2190979A1 (en) | 1994-06-02 | 1995-12-14 | John Michael Cox | Substituted pyrrolidone, thiazolidones or oxazolidones as herbicides |
| US5612353A (en) | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
| GB9515411D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
| GB9727523D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| GB9727521D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Substituted 2-benzylamino-2-phenyl-acetamide compounds |
| SI1458386T1 (sl) * | 2001-12-27 | 2007-08-31 | Ortho Mcneil Pharm Inc | Aroil pirol heteroeril in metanoli, uporabni za zdravljenje motnje centralnega živčnega sistema |
-
2003
- 2003-11-21 EP EP03026779A patent/EP1533298A1/de not_active Withdrawn
-
2004
- 2004-11-16 MX MXPA06005626A patent/MXPA06005626A/es active IP Right Grant
- 2004-11-16 RU RU2006117123/04A patent/RU2395495C2/ru active
- 2004-11-16 DE DE602004015497T patent/DE602004015497D1/de not_active Expired - Lifetime
- 2004-11-16 ES ES04819593T patent/ES2309600T3/es not_active Expired - Lifetime
- 2004-11-16 DK DK04819593T patent/DK1685103T3/da active
- 2004-11-16 AT AT04819593T patent/ATE402922T1/de active
- 2004-11-16 PL PL04819593T patent/PL1685103T3/pl unknown
- 2004-11-16 SI SI200430812T patent/SI1685103T1/sl unknown
- 2004-11-16 US US10/579,675 patent/US7968592B2/en not_active Expired - Fee Related
- 2004-11-16 BR BRPI0416816A patent/BRPI0416816B8/pt not_active IP Right Cessation
- 2004-11-16 JP JP2006540284A patent/JP2007511564A/ja active Pending
- 2004-11-16 WO PCT/EP2004/012957 patent/WO2005054190A1/en not_active Ceased
- 2004-11-16 NZ NZ547295A patent/NZ547295A/en not_active IP Right Cessation
- 2004-11-16 PT PT04819593T patent/PT1685103E/pt unknown
- 2004-11-16 EP EP04819593A patent/EP1685103B1/de not_active Expired - Lifetime
- 2004-11-16 CN CNA2004800340633A patent/CN1882536A/zh active Pending
- 2004-11-16 AU AU2004295048A patent/AU2004295048B2/en not_active Ceased
- 2004-11-16 CA CA2546653A patent/CA2546653C/en not_active Expired - Fee Related
-
2006
- 2006-05-18 KR KR1020067009717A patent/KR101208390B1/ko not_active Expired - Fee Related
- 2006-05-18 NO NO20062231A patent/NO337679B1/no not_active IP Right Cessation
- 2006-05-18 IL IL175754A patent/IL175754A/en active IP Right Grant
-
2008
- 2008-09-19 CY CY20081101022T patent/CY1108359T1/el unknown
-
2009
- 2009-11-02 US US12/610,660 patent/US8063039B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0956855T3 (da) | Immunhæmmende effekter af 8-substituerede xanthin-derivater | |
| MY145140A (en) | Amide derivatives, process for preparation thereof and use thereof as insecticide | |
| EP1798226A4 (de) | Triazolderivat | |
| MX2009013119A (es) | Derivados de 2-[2-(fenil)etilamino]alcanamida sustituidos y su uso como moduladores del canal de sodio y/o potasio. | |
| AR058720A1 (es) | Derivados 2-feniletilamino y composicion farmaceutica | |
| CY1106930T1 (el) | Παραγωγα κυκλοπεντυλο-ομαδας | |
| CY1108359T1 (el) | Παραγωγα 3-αμινοπυρρολιδονης | |
| DK1689708T3 (da) | N-acyl-N'-benzylalkylendiamino-derivat | |
| ATE479690T1 (de) | Thienoä2,3-büpyridin derivate | |
| ATE553099T1 (de) | Substituierte benzylaminoalkylenheterocyclen | |
| SE0400440D0 (sv) | Novel Cinnamic Amides | |
| DK1899331T3 (da) | Homomorpholinoxazolidnoner som antibakterielle midler | |
| WO2005110406A3 (en) | Phenyl derivatives for the treatment of abnormal cell growth | |
| FR2903698B1 (fr) | Nouveaux derives de 5-thioxylopyranose. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1685103 Country of ref document: EP |